Angeliq vs Activella: How the Two Labels Actually Differ

This page contains affiliate links. The HRT Index may earn a commission if you use one, at no extra cost to you. It does not change what we verify or what we conclude. Full disclosure.

Angeliq vs Activella comes down to four decision-driving differences: the progestin, the price, one FDA-approved use, and one Angeliq-specific safety screen. Both are once-daily estradiol-plus-progestin pills for postmenopausal women with a uterus. In a July 2026 coupon snapshot, the lowest no-signup price for 28 tablets was about $187 for Angeliq versus about $32 for generic Activella. Activella also carries an osteoporosis-prevention indication that Angeliq does not.

The five differences that decide most choices

Sources: current DailyMed labels for both products and a SingleCare price snapshot, all checked 27 July 2026. Prices vary by pharmacy, ZIP code and date, and are not guaranteed.

Here’s the part almost nobody tells you

One reason Angeliq gets attention online is its reputation for less bloating, or a blood-pressure benefit.

The blood-pressure studies behind much of that reputation used 1 mg, 2 mg, or 3 mg of drospirenone.

The Angeliq sold in the United States contains 0.25 mg or 0.5 mg.

We’ll show you the trials, the doses, and what Angeliq’s own FDA label says about blood pressure. It isn’t what the internet says.

Angeliq vs Activella: the differences that actually matter

Angeliq (drospirenone + estradiol) and Activella (estradiol + norethindrone acetate) are both FDA-approved to treat hot flashes and vaginal atrophy in postmenopausal women with a uterus. Activella carries a third approved use that Angeliq does not: prevention of postmenopausal osteoporosis. Angeliq’s label adds contraindications for renal impairment and adrenal insufficiency, plus a hyperkalemia warning, that Activella’s label does not contain.

We pulled up both current FDA labels side by side on July 27, 2026 and read them line by line. Here is every place they genuinely diverge.

Label rows: DailyMed records for Angeliq (Bayer) and Activella (Amneal), read 27 July 2026. Generic approval: FDA 2025 First Generic Drug Approvals list. Prices: SingleCare snapshot, 27 July 2026.

Four rows in that table decide most real-world choices: the progestin, the osteoporosis line, the two extra contraindications, and the price. Everything below unpacks them in the order your brain needs them.

Which one is right for you?

Neither pill is universally safer or more effective. Generic estradiol/norethindrone acetate has multiple commercially available products and a dramatically lower current cash-price snapshot, which makes it the practical lower-cost option to raise first when a clinician considers either regimen appropriate. Angeliq is a targeted choice that needs a specific reason and an extra safety review.

Find yourself here. This is an editorial framework for your conversation, not a clinical decision tree.

Cost is your deciding factor. Start with generic estradiol/norethindrone acetate. It uses the same estradiol molecule, and at the compared 1 mg estradiol strengths its current cash-price snapshot is dramatically lower.

You’ve tried a norethindrone-containing HRT and couldn’t tolerate the progestin. That’s a legitimate reason to ask about drospirenone specifically. Bring the details of what actually happened — not just “it didn’t agree with me.”

Bone protection is part of why you’re taking this. Only Activella carries that indication. Read the bone section below before you treat it as a slam dunk, because the label itself adds a catch.

You have renal impairment, adrenal insufficiency, or take medicines that can raise potassium. This is the most important screen on this page. Skip to the safety section.

Vaginal dryness or painful sex is your only symptom. Both labels say the same thing: consider a topical vaginal product first. A daily whole-body pill may be more medicine than you need. Start with our guide to vaginal estrogen.

You’ve had a hysterectomy. Both pills are labeled for women with a uterus. Many women after a total hysterectomy don’t need a progestogen, but that depends on the surgery and your history. Talk to a clinician about estrogen-alone options.

The one thing we won’t do

We’re not going to tell you which of these two pills is right for you. And you should be a little suspicious of any page that does.

There are sites that will rank these first and second like laptops. We won’t, because the honest answer depends on things a webpage can’t see — your kidney function, your blood pressure medication, your bone density, whether bleeding or bloating bothers you more, and what your plan covers this year.

What we can do is the work nobody else bothered with: open both FDA labels, read them against each other, and hand you the differences. That turns a frustrating appointment into a five-minute conversation where you already know the questions.

Not sure which description above sounds like you? Find My HRT Path narrows it to your symptoms, your state, and your coverage in about 90 seconds — and tells you when online care isn’t where you should start.

What’s actually different inside the two pills?

The estrogen in Angeliq and Activella is the same molecule: estradiol, chemically identical to the estradiol your ovaries made before menopause. The difference is the progestin, the second hormone added to protect the uterine lining. Angeliq uses drospirenone, a spironolactone analog with antimineralocorticoid activity. Activella uses norethindrone acetate, a 19-nortestosterone-derived progestin.

Everything else that separates these two drugs flows downstream from that one swap.

Drospirenone is described in Angeliq’s label as a synthetic progestin and spironolactone analog with antimineralocorticoid activity — meaning it works against aldosterone, the hormone that tells your body to hold onto salt and water. That’s where the “doesn’t cause bloating” reputation comes from. The label also notes antiandrogenic activity in animals and in laboratory studies.

Norethindrone acetate comes from the 19-nortestosterone family. It’s been used in women’s health since the 1960s. It’s a workhorse: reliable at protecting the uterine lining, extremely well characterized, and inexpensive because multiple manufacturers make it.

Both products contain estradiol, which is chemically identical to the estradiol your body makes. Neither contains micronized progesterone — Angeliq pairs estradiol with drospirenone, Activella pairs it with norethindrone acetate, and both of those are synthetic progestins. “Bioidentical” on its own is not a safety or superiority claim, and we’re not using it as one.

The dose-order trap that trips up almost everyone

This one is worth thirty seconds, because it causes real confusion at the pharmacy.

The two labels write their numbers in opposite order.

Angeliq 0.5 / 1
= 0.5 mg drospirenone + 1 mg estradiol
   (progestin first)

Activella 1 / 0.5
= 1 mg estradiol + 0.5 mg norethindrone acetate
   (estrogen first)

Look at those two lines. “0.5/1” and “1/0.5.” They look like mirror images of the same prescription. They aren’t. In one, the first number is the progestin. In the other, the first number is the estrogen.

We did not find this warning in any of the comparison pages we reviewed on July 27, 2026. It matters most when you’re switching, when a pharmacist substitutes something, or when you’re comparing what you took last year to what you’re being offered now. Always read the ingredient names, not just the numbers.

Are these birth control pills?

No. Both are menopause medications. Neither is approved or reliable for preventing pregnancy. If you’re perimenopausal and still need contraception, that’s a separate conversation with your clinician — don’t assume these cover it.

Which one is FDA-approved for what?

Both Angeliq and Activella are FDA-approved to treat moderate-to-severe hot flashes and moderate-to-severe vaginal atrophy in postmenopausal women with a uterus. Activella carries a third approved use that Angeliq does not: prevention of postmenopausal osteoporosis, on both strengths. Both labels advise considering a topical vaginal product first when vaginal symptoms are the only concern.

Source: current DailyMed labels for both products, read 27 July 2026.

That third row is a checkable difference in what FDA has agreed each drug can claim. It’s not our opinion and it’s not a review-site ranking. It’s printed on the labels.

One nuance most pages skip: the lower strength of each drug is approved for hot flashes but not for vaginal atrophy. If vaginal symptoms are a real part of why you’re taking this, the strength on your prescription matters.

Which works better for hot flashes: Angeliq or Activella?

No equal-dose head-to-head trial establishes a hot-flash winner. Both products are FDA-approved for moderate-to-severe vasomotor symptoms. The one direct comparative trial used unequal estradiol doses and treated symptom improvement as an exploratory outcome, with similar improvement reported between its two groups.

This is the question most women actually want answered, and the honest answer is unsatisfying in a useful way.

Each drug earned its hot-flash indication in its own trials, against placebo, years apart, in different populations. That is enough for FDA to approve both. It is not enough to rank them.

What Angeliq’s label shows. In a placebo-controlled trial of the 0.25 mg/0.5 mg strength, women started with an average of 10.68 hot flushes a day. At week 12, the Angeliq group was down 7.71 a day versus 4.54 on placebo — a difference of 3.17 fewer hot flushes per day (95% CI −3.97 to −2.37, p<0.0001), with a significant difference already at week 4.

One detail worth knowing about the higher strength. The current US label supports the marketed 0.5 mg drospirenone/1 mg estradiol strength for vasomotor symptoms through evidence that included bioequivalence of its estradiol component, rather than a dedicated efficacy trial described for that marketed strength. And the tablet used in that bridging study contained 2 mg of drospirenone — four times what’s in the US product.

What Activella’s label shows. A 12-week randomized trial of the 1 mg/0.5 mg strength versus estradiol alone and placebo found significantly reduced hot flush number and intensity at weeks 4 and 12. A separate 24-week European trial of the 0.5 mg/0.1 mg strength in 577 women found the same pattern.

What you cannot do with those numbers. Put them side by side and declare a winner. Different trials, different eras, different entry criteria, different definitions. Activella’s own label says it directly: adverse reaction rates from one drug’s trials cannot be compared to another drug’s.

The practical read: both work for hot flashes in the population each was studied in. If one doesn’t work well enough for you, that’s a dose or route conversation, not proof the other brand would have been better.

Which one protects your bones?

Activella is FDA-approved to help prevent postmenopausal osteoporosis. Angeliq is not, and its US label contains no bone density data. In two 2-year placebo-controlled trials in Activella’s label, lumbar spine bone density rose 3.8% and 5.4% on Activella while placebo groups lost 2.1% and 0.9%.

Here are the actual numbers from Activella’s label — more detail than you’ll find almost anywhere else.

The evidence context, which the numbers alone don’t give you:

• 462 postmenopausal women across two randomized, placebo-controlled trials
• Two years of treatment, with calcium supplementation
• Enrollment required baseline lumbar-spine T-scores above −2.0
• Measured by DXA scan; bone mineral density was the endpoint
• The current US Angeliq label contains no bone-density section at all
• Neither trial establishes fracture superiority over any other medication

Source: Activella prescribing information, Section 14.4.

Now the honest catch, which comes off the same label.

“Prevention” is not “treatment.” These trials enrolled women whose spine T-scores were above −2.0. Preventing bone loss in a relatively healthy skeleton is a different job from treating osteoporosis you already have.

And Activella’s label adds its own limitation: when osteoporosis prevention is the only reason you’d take it, consider non-estrogen medicines first, and reserve estrogen for women at significant risk.

So the fair reading: when hot flash treatment and osteoporosis prevention are both goals, Activella’s label includes both indications. That does not establish fracture superiority or make it the right osteoporosis treatment for every patient. If bones are the only reason, ask whether a bone-specific drug is the better tool.

The US Angeliq label does not contain an osteoporosis-prevention indication or a bone-density efficacy section, and it does not state why that indication was not obtained.

Does Angeliq really help with bloating and blood pressure?

The cited blood-pressure studies behind drospirenone’s reputation used 1 mg, 2 mg, or 3 mg of drospirenone. Current US Angeliq contains 0.25 mg or 0.5 mg. Angeliq’s US prescribing information makes no blood-pressure claim, and its Section 5.8 states that a generalized effect of estrogen therapy on blood pressure was not seen in a large randomized, placebo-controlled trial.

This is the finding that changed how we wrote this page.

If you’ve read that Angeliq is the HRT that lowers blood pressure, or the one that won’t make you puffy, that reputation came from real science. Here is exactly what that science used.

Read the last row against the ones above it. The lowest arm in Bayer’s own blood-pressure trial was 1 mg — still double the strongest US tablet. Across the cited study doses and the two current US strengths, the research used 2 to 12 times as much drospirenone.

Two things confirm this isn’t a misreading

One. Bayer’s own trial NCT00446199 compares “low dose Angeliq (0.5 mg E2 and 0.25 or 0.5 mg DRSP)” against “Angeliq (1 mg E2 and 1, 2 or 3 mg DRSP).” The company treats these as two different dose families.

Two. Trial NCT00420342 ran 0.5 mg drospirenone and 2.0 mg drospirenone side by side — both labeled “Angeliq.” Same brand name. Different markets. Four times the progestin.

What Angeliq’s own label says about blood pressure

Section 5.8 is titled Elevated Blood Pressure. Not “blood pressure benefit.” It notes that substantial increases in blood pressure have been attributed to idiosyncratic reactions to estrogens in a small number of case reports, and that in a large randomized, placebo-controlled trial, a generalized effect of estrogen therapy on blood pressure was not seen.

That’s the entire entry. There is no antihypertensive indication, claim, or benefit statement anywhere in the US prescribing information. Angeliq is not a blood-pressure medication.

What this does and does not mean

Let’s be precise, because precision is the whole point.

This is not evidence that drospirenone stops working at lower doses. We’re not making that claim and nobody should. Lower doses of a drug can still do useful things.

What it does mean: the striking numbers you may have read were generated at 2 to 12 times the drospirenone in your US prescription, the US label makes no such claim, and whether that effect scales down has not been established in US labeling.

If a clinician recommends Angeliq for a reason specific to you, that reason may be perfectly sound. But “I heard it’s the one that lowers blood pressure” is not, by itself, a reason to pay roughly six times more. That’s a fair question to put to your prescriber — and now you can put it precisely.

One label detail cuts the same direction. In Angeliq’s own placebo-controlled trial of the 0.25 mg/0.5 mg strength, peripheral edema was reported by 2.2% of women on Angeliq versus 1.1% on placebo. Small numbers either way, and one adverse-event table doesn’t prove drospirenone caused the difference. But it is not evidence that the current US Angeliq dose prevents puffiness.

Which one causes less bleeding?

A one-year randomized trial of 662 postmenopausal women compared low-dose Angeliq (0.25 mg drospirenone/0.5 mg estradiol) directly against 0.5 mg norethindrone acetate/1 mg estradiol — the Activella combination. No evaluable woman in either group had an endometrial-biopsy result of hyperplasia or worse. Reported amenorrhea favored the Angeliq arm in months 1–3, and both groups reached roughly 80% by months 10–12.

Most drug comparisons can’t answer this honestly, because the two products were studied separately. Here, there’s an actual head-to-head.

Genazzani AR, Schmelter T, Schaefers M, Gerlinger C, Gude K. One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women. Climacteric. 2013 Aug;16(4):490–8. PMID 23531117.

Read this carefully before you conclude anything

The estradiol doses were not equal. The Angeliq arm got 0.5 mg of estradiol. The comparator arm got 1 mg — twice as much. Because the estradiol doses differed, this trial cannot isolate whether the early bleeding difference came from the progestin, the estradiol dose, or both.

It didn’t test every marketed strength. The trial compared the lower current US Angeliq strength with the higher Activella strength. If your prescription is Angeliq 0.5/1 mg, this study did not test your pill.

The study was funded by the company that makes Angeliq, and four of the five authors were Bayer employees. That doesn’t make it wrong — it’s a peer-reviewed randomized trial. It means you weight the headline accordingly.

What this study cannot answer

• An equal-dose comparison of the two progestins
• Every marketed strength combination
• What your bleeding will do
• Long-term comparative safety beyond one year
• Which product is more effective overall

The finding we’d actually hang our hat on

In this one-year trial, no evaluable woman in either group had hyperplasia or worse, and the two groups had similar amenorrhea rates by months 10–12. If early spotting is what you dread most, there’s a signal favoring the low-dose drospirenone combination in months 1–3 — a signal, not a promise, and one the unequal estradiol doses prevent anyone from attributing cleanly.

For context, each label’s own numbers

Not comparable to each other — different trials, different definitions — but worth seeing:

• Activella 1 mg/0.5 mg: about 86% of women had no bleeding or spotting by 12 months
• Activella 0.5 mg/0.1 mg: 88% had none by 6 months
• Angeliq 0.5 mg/1 mg: about 22% still reported some bleeding or spotting at 12 months
• Angeliq 0.25 mg/0.5 mg: about 15% still reported some at 12 months

About bleeding: what both labels actually tell you

Bleeding and spotting occurred during treatment in the clinical trials and often decreased over time.

Which is safer: Angeliq or Activella?

Neither product is universally safer. Their labels share the major estrogen-plus-progestin contraindications, but Angeliq’s label adds contraindications for renal impairment and adrenal insufficiency, plus dedicated hyperkalemia and hyponatremia warnings, that Activella’s label does not contain.

This is the section to read slowly if you take other daily medications.

Who should not take Angeliq?

Angeliq’s label lists two contraindications that Activella’s does not.

Renal impairment. Angeliq is contraindicated in women with renal impairment. Drospirenone works against aldosterone, and your kidneys are central to clearing potassium.

Adrenal insufficiency. Also contraindicated, for the same reason through a different route.

Angeliq additionally carries Section 5.2 (Hyperkalemia) and Section 5.14 (Hyponatremia). Activella’s label has no counterpart to either.

The medicine-cabinet check

Angeliq’s Section 5.2 names the drug classes that need attention. Read this against your own shelf:

• NSAIDs — ibuprofen, naproxen and similar, especially taken regularly
• Potassium-sparing diuretics
• Potassium supplements
• ACE inhibitors — names usually ending in -pril (lisinopril, enalapril)
• ARBs — names usually ending in -sartan (losartan, valsartan)
• Heparin
• Aldosterone antagonists — such as spironolactone

The label also says to consider monitoring serum potassium during the first month in high-risk patients taking strong CYP3A4 inhibitors long-term and concomitantly — certain antifungals, some HIV or hepatitis C medications, and clarithromycin.

Taking one of these does not by itself rule out Angeliq. The label calls for caution, not an automatic no. What it does mean is that Angeliq requires a specific medication and potassium-risk review that Activella does not — and that review may change the choice.

That combination — a woman in her fifties on a blood pressure pill who takes ibuprofen for her knees — is not rare. It’s a Tuesday. If that’s you, this is a real conversation to have, not a formality.

What rules out both pills

These are contraindications on both labels:

• Undiagnosed abnormal genital bleeding
• Breast cancer, now or in the past
• Estrogen-dependent neoplasia
• Active DVT or pulmonary embolism, or a history of either
• Active arterial thromboembolic disease such as stroke or heart attack, or a history of either
• Hepatic impairment or disease
• A known thrombophilic disorder — protein C, protein S, or antithrombin deficiency
• Known anaphylactic reaction, angioedema, or hypersensitivity to the product

If any of these applies, this drug comparison is not your next step. The next step is clinician evaluation and a discussion of appropriate alternatives, which may include non-hormonal options.

Did FDA remove the boxed warning from Angeliq or Activella in 2026?

No. The current Bayer Angeliq label and the Amneal Activella label reviewed here both still carry boxed warnings covering cardiovascular disorders, probable dementia, breast cancer, and endometrial cancer. FDA requested broader menopausal hormone therapy labeling changes in November 2025 and has been approving them product by product; neither of these two labels had received that revision as of July 27, 2026.

Let’s talk about the thing you actually think about at 2am.

You’ve read the block of capital letters at the top of the label. Heart attack. Stroke. Dementia. Breast cancer. It’s frightening, and every comparison page skips past it because it’s identical on both drugs — so it doesn’t help you choose. But it’s probably the biggest thing standing between you and filling the prescription. So here’s what we found.

In November 2025, FDA formally asked manufacturers of menopausal hormone therapy to revise these labels. The requested changes are substantial: remove the cardiovascular, breast cancer, and probable dementia language from the boxed warning; remove the “lowest dose for the shortest time” instruction; and add language addressing treatment for women under 60 or within 10 years of menopause.

In February 2026, FDA announced approval of updated labeling for a first group of six products.

Neither of these two is in that group. We checked both labels ourselves on July 27, 2026.

One detail that will fool you if you check yourself

Look up Angeliq on DailyMed and the record says “Updated March 2, 2026.” You’d reasonably assume the 2026 changes have landed.

They haven’t. Open the label and it reads “Revised: 12/2023.” The Recent Major Changes box lists only the boxed warning from 10/2023 and one warnings section from 12/2023. The boxed warning still contains all four items. The Amneal Activella record sits at a 11/2023 revision.

What to do with this

These current boxed warnings remain the operative labeling for Bayer’s Angeliq and the Amneal Activella label we reviewed. Read them as what they are: what FDA currently requires on these two products.

And know that they are mid-revision. FDA has asked for changes across the category and is approving them one product at a time. These two haven’t had their turn.

That does not mean the risks vanished. FDA asked for revisions to how risks are communicated. That’s a different thing from saying the underlying risks disappeared.

Check your own bottle. Estradiol/norethindrone acetate is listed under multiple US labelers. Look at the manufacturer name on your package and pull up that manufacturer’s current DailyMed record — this page directly reviewed the Amneal Activella label, which may not be the one in your hand.

If the boxed warning is what’s been holding you back, this is the context you were missing, and it’s a good reason to have the conversation rather than quietly not filling the prescription. Our benefits and risks guide goes deeper on what the underlying data showed.

Which has fewer side effects or less weight gain?

Neither product has been shown to cause less weight gain than the other. Both labels list overlapping side effects including headache, breast tenderness, abdominal pain, and irregular bleeding. Angeliq’s label carries potassium-related warnings that Activella’s does not. Side-effect rates from separate trials cannot be directly compared.

We’re going to disappoint you slightly here, then explain why the disappointment is the useful part.

From Angeliq’s label — most common reactions in at least 1% of users: gastrointestinal and abdominal pain, female genital tract bleeding, breast pain and discomfort, headache.

Within Angeliq’s pooled label data, formulations containing 1 mg estradiol reported more breast pain (17.9% vs 6.2%) and more genital tract bleeding (14.0% vs 2.5%) than formulations containing 0.5 mg estradiol. Those pooled datasets also involved different drospirenone doses and different trial populations, so they don’t isolate estradiol dose as the cause.

From Activella’s label — reactions at 5% or more: back pain, headache, extremity pain, nausea, diarrhea, gastroenteritis, insomnia, emotional lability, upper respiratory infection, sinusitis, nasopharyngitis, weight increase, breast pain, postmenopausal bleeding, endometrial thickening.

Activella’s list looks longer. It mostly isn’t. It’s a different reporting threshold and a different coding system from a different era of trials.

The honest conclusion: the available label tables are not normalized enough to identify an overall side-effect winner. Different designs, different populations, different thresholds, different coding dictionaries. Activella’s own label says it plainly — adverse reaction rates from one drug’s trials cannot be directly compared to another drug’s.

Anyone who tells you one of these has fewer side effects is reading two incompatible tables and picking a favorite.

On weight and bloating specifically

We’re not going to tell you Angeliq prevents weight gain. Its label doesn’t say that, it isn’t a weight-loss drug, and its own trial reported peripheral edema at 2.2% versus 1.1% on placebo. Weight increase appears on Angeliq’s list of reactions leading to discontinuation.

Menopausal weight change is driven by a tangle of things — muscle loss, sleep, activity, age, the hormonal shift itself. Picking one progestin over another isn’t the lever most women hope it is.

What real women say — and why it isn’t proof

“I’m feeling more like myself.”

“The bleeding is what’s driving me crazy.”

“Worked for hot flushes, mood swings, low libido, but experienced bleeding…”

Individual experiences from anonymous public reviews. Not clinical evidence, not proof of cause and effect, and not typical results.

These three selected comments illustrate concerns readers raise, including bleeding. They cannot establish how common any concern is across users.

How much do Angeliq and Activella cost in 2026?

In a July 27, 2026 coupon snapshot for 28 tablets at the 1 mg estradiol strengths, the lowest displayed price without a signup bonus was about $187 for Angeliq versus about $32 for generic estradiol/norethindrone acetate. Angeliq’s average cash price displayed at about $241. At the lowest no-signup prices from the same source, the difference was about $156 per 28-day supply.

Coupon prices are estimates, not guaranteed at the counter, and vary by pharmacy and location. A “28-day supply” is 28 tablets, not a calendar month.

We normalized these deliberately. Most pages quoting drug prices mix a signup-bonus price against an average retail price against a different pharmacy’s cash price, and the comparison falls apart. These two rows are the same source, same day, same quantity, same conditions.

“Generic Activella” is not one thing

The same molecules are sold three ways in the US:

1. Brand Activella
2. Branded generics — sold under their own names, such as Amabelz, Lopreeza, and Mimvey
3. Generic estradiol/norethindrone acetate, labeled by manufacturer name

If you walk in and ask for “the generic,” which one lands in your bag depends on what that pharmacy stocks and how it’s packaged. Some listings display three 28-tablet packages rather than one, which makes online price comparisons look wilder than they are.

Ask the pharmacy to compare the products and billing routes it can actually dispense. Discount cards generally can’t be combined with insurance, and the pharmacy decides which price it can process — so ask them to run whichever is cheaper.

On insurance

Coverage depends on your plan, formulary tier, pharmacy network, and any prior-authorization or step-therapy rules. Three things are generally true:

• Brand and generic sit on different tiers, and the gap can be large.
• A discount card price is sometimes lower than your copay. Ask the pharmacist to check both.
• Authorization rules change every plan year — including for drugs you’ve taken for years.

Angeliq patient assistance

Angeliq currently appears in Bayer’s US patient assistance screening tool. Eligibility depends on income, household size, insurance status and residence, and those criteria change. Check Bayer’s own eligibility tool rather than trusting a number published somewhere else.

Is Angeliq harder to get than Activella?

FDA approved the first generic drospirenone/estradiol product referencing Angeliq — from Novast Laboratories, ANDA 218031 — on October 28, 2025. FDA states that approved drugs are not always available on or after the listed approval date. Commercial launch and routine US pharmacy stocking were not verified as of July 27, 2026. Multiple estradiol/norethindrone acetate products are commercially available.

We verified the approval directly on FDA’s 2025 First Generic Drug Approvals list. Row 78: Drospirenone and Estradiol Tablet, Novast Laboratories Ltd., referencing Angeliq (NDA 021355), approved 10/28/2025.

So “is there a generic Angeliq?” doesn’t have a clean yes-or-no answer. It has this one:

Approved, launched, and stocked are three different things

FDA says this itself, right on that page: approved drugs are not always available on or after the listed approval date, and you should contact the applicant about availability.

This is why “Angeliq has no generic” and “generic Angeliq is available now” are both wrong. One is FDA-approved. Whether it exists at your pharmacy is a question only your pharmacy can answer.

What the supply picture looks like

Multiple estradiol/norethindrone acetate products are commercially listed. The currently marketed Angeliq brand label is Bayer’s, and Novast holds an FDA-approved generic whose commercial launch and pharmacy stock we could not verify. That narrower verified supply record is worth knowing before you build a routine around a medication.

We did not find an FDA-declared national shortage of Angeliq. If your pharmacy has told you they can’t get it, the useful next move isn’t confirming how common that is — it’s asking them the NDC question above and getting a written answer you can take to your prescriber.

Can you switch from Angeliq to Activella?

Angeliq and Activella are not dose-for-dose substitutes. Neither label provides a universal Angeliq-to-Activella conversion or switching schedule. Angeliq’s “may start at any time” language applies when starting Angeliq from another continuous-combination product — it does not tell a patient when to start Activella after stopping Angeliq. Switching is a prescriber decision.

Most women land on this page because something forced the question. Insurance changed. The pharmacy couldn’t fill it. The price jumped. Something’s bleeding or aching.

Here’s the part we want to be exact about, because it’s easy to get backwards.

What the Angeliq label says when starting Angeliq: women who don’t take estrogens, or who are changing from a continuous-combination product, may start Angeliq at any time. Women changing from a continuous sequential or cyclic hormone therapy should complete the current cycle before starting Angeliq.

What neither label tells you: how or when to start Activella after stopping Angeliq. There is no published conversion between drospirenone and norethindrone acetate, and no universal switching schedule in either label.

What has to be decided by your prescriber: which product, which strength, when to start, and what follow-up looks like.

The three-question script

Print this or screenshot it. You want a reason, not just a yes.

1. “What’s the specific reason you’re choosing this progestin for me?” If there’s a real clinical reason, you’ll learn something. If it’s habit, you’ve opened the door.
2. “Is this strength approved for all the symptoms I’m treating?” Remember: the lower strengths cover hot flashes but not vaginal atrophy.
3. “What bleeding should I report, and how do I reach you quickly if it happens?” Both labels say report any vaginal bleeding as soon as possible — so ask how, not whether.

What to bring

Current product and strength · generic manufacturer if you know it · when you last took it · symptom changes · bleeding dates · every medicine and supplement you take · your kidney and adrenal history · what your insurance or pharmacy actually quoted you.

What we won’t give you

A start date. A dose conversion. A taper. A gap. Not because of caution theater — because those depend on which product, which strength, and which body. Anyone handing you a switching schedule sight unseen is guessing with your body.

What if neither pill is right for you?

Both Angeliq and Activella are oral, systemic hormone therapy for postmenopausal women with a uterus. If vaginal symptoms are your only concern, both labels advise considering a topical vaginal product first. Route can change the risk discussion. And after a hysterectomy, a progestogen may not be needed at all.

Sometimes the right answer to “which of these two?” is “neither, and here’s why.”

On route specifically: ACOG notes that orally administered estrogen may exert a greater prothrombotic effect through hepatic first-pass exposure, while transdermal estrogen has less effect on several prothrombotic substances. That’s a genuine discussion point with your clinician. It does not make a patch appropriate or risk-free for everyone.

One 2026 note if you’re considering a patch: ASHP lists estradiol transdermal systems in current shortage status, last revised July 1, 2026. Availability differs by product, strength and manufacturer, so check the specific patch with your pharmacy.

On micronized progesterone: neither product contains it. Estradiol plus micronized progesterone is a different prescription regimen with a different evidence and safety profile — worth asking about, but not a swap you make at the counter.

What if your prescriber won’t have this conversation?

Not every clinician is comfortable with menopausal hormone therapy. In a 2013 survey, 20.8% of 510 responding OB-GYN residents reported having a formal menopause curriculum. If you’ve been dismissed or can’t get an appointment, a telehealth clinician may be able to evaluate you and send an appropriate prescription to your local pharmacy.

That statistic isn’t an insult to your doctor. It’s a gap in a training system, and it explains a lot of frustrating appointments.

If you already have a prescriber willing to work with you, stay with them. Bring the questions from this page. No telehealth service beats that.

The honest part first

The public provider materials we reviewed do not confirm whether Angeliq or Activella is available through any given provider’s current formulary. A telehealth clinician may be able to evaluate your situation and send an appropriate prescription to a local pharmacy, where you use your insurance or a discount card. But we’re not going to imply that any provider is a guaranteed route to either of these specific brands, because we haven’t verified that.

That’s the difference between “here’s a clinician who takes menopause seriously” and “here’s where to get Angeliq.” Only the first one is something we can stand behind today.

Hers publishes menopause materials listing estradiol and progesterone options, but does not publicly confirm Angeliq or Activella. Don’t treat it as a route to either medication unless you verify the formulary directly.

Winona and Inner Balance are not on this page. Both are compounded-focused. Compounded products are not FDA-approved, and FDA does not review them for safety, effectiveness, or quality before marketing. This page compares two FDA-approved brand-name products, and blending the two categories would mislead you. We’d rather tell you that than pad a list.

Midi Health

Midi is one route to a menopause-focused clinician. Here are its limits first, because they disqualify some readers entirely.

Midi cannot treat Medicaid or Medi-Cal patients at all, even self-pay. It is not enrolled with Medicare — Medicare beneficiaries may self-pay, but no claim gets filed. Self-pay is $250 for a first visit and $150 for follow-ups, and medication is billed separately at your pharmacy.

Because Midi doesn’t run a flat-fee subscription, it can bill insurance directly — it’s in-network with most PPO plans, operates in all 50 states, and sends prescriptions to your own pharmacy, so you can use your drug benefit or a discount card on the medication itself. For a woman with commercial insurance whose real problem is that nobody will take the conversation seriously, that structure works.

Sesame

Sesame is a marketplace rather than a clinic. You browse clinicians, see the price before booking, and choose video or in-person — including gynecology in many cities. Sesame advertises general telehealth visits from $37; menopause and gynecology pricing varies by clinician, location and appointment type.

One firm limit: Sesame requires users to certify they are not Medicare, Medicaid, or TRICARE beneficiaries. If you’re on any federal program, this isn’t your option.

What we actually verified

You should be able to check our work. Here’s exactly what we opened, when, and what we couldn’t confirm.

Verified firsthand on July 27, 2026:

• Angeliq prescribing information — DailyMed, set ID 761834c2-6b61-4583-84c2-f1ca4a97c4f2 (Bayer). Record updated 2 March 2026; label Revised 12/2023. Boxed warning, contraindications, Sections 5.2, 5.8, 5.14, and the Section 14 clinical studies read in full.
• Activella prescribing information — DailyMed, set ID d4b0c1dd-aae9-4ca2-958c-71dbe5d0fab0 (Amneal). Record updated 30 November 2023; label Revised 11/2023. Indications, contraindications, and the Section 14.4 bone density tables read in full.
• FDA 2025 First Generic Drug Approvals list — confirming ANDA 218031, Novast Laboratories, drospirenone and estradiol tablets, approved 28 October 2025, plus FDA’s note that approval doesn’t guarantee availability.
• The Genazzani 2013 head-to-head trial — PubMed record PMID 23531117: design, 662 participants, ages 40–65, both treatment arms, primary endpoint, and conclusion.
• The drospirenone dose record — PubMed abstracts for Preston 2005 (PMID 15925739), Preston 2007 (PMID 17224857) and White 2005 (PMID 16186434), plus ClinicalTrials.gov records NCT00102141, NCT00185328, NCT00420342 and NCT00446199.
• Pricing — a SingleCare snapshot for both products at matched quantity and strength class, checked 27 July 2026, recorded with and without the one-time signup bonus.

Taken from published sources we did not independently reproduce:

• The month-by-month amenorrhea percentages and the funding and author-affiliation details from the 2013 trial’s full text.
• ASHP’s current shortage listing for estradiol transdermal systems, last revised 1 July 2026.
• ACOG’s statement on route of administration and prothrombotic effect.

What we could not verify, and are not claiming:

• Whether the FDA-approved generic Angeliq has commercially launched or is stocked anywhere.
• Whether brand Activella is still actively marketed alongside its generics.
• Current label revision dates for estradiol/norethindrone acetate labelers other than Amneal.
• Any national shortage designation for Angeliq. We found none.
• Whether any named telehealth provider can prescribe Angeliq or Activella specifically.
• Your insurance coverage, your pharmacy’s stock, your copay, or whether either medication is appropriate for you.

How this page was made: We applied The HRT Index Verification Standard — read the published prices, separate FDA-approved from compounded, verify availability and insurance, and re-check on a fixed schedule. For this page specifically, we reviewed the cited FDA and DailyMed records, the named comparative trial, and the displayed price sources, and marked generic launch, local pharmacy stock, exact provider formulary access, and individual insurance coverage as unresolved where they were not directly verified.

Who wrote it: The HRT Index Editorial Team. This is editorial research, not clinician-reviewed medical advice, and we’ve labeled it that way on purpose. See our editorial standards and corrections policy.

Angeliq vs Activella FAQ

Still not sure which HRT program is right for you?

You’ve got the label differences now. The questions left — which route fits your risk history, whether your state and insurance work with a given provider, and whether online care is even the right starting point — are the ones a comparison table can’t answer.

You’ve done more homework than most people who walk into that appointment. Finish it.

The HRT Index is an independent decision resource for online menopause and HRT care. This page is educational and is not medical advice, a diagnosis, or a treatment recommendation. It has not been reviewed by a clinician. Always talk with a qualified healthcare professional about your own situation. FDA-approved and compounded medications are labeled distinctly throughout, and compounded products are never presented as equivalent to FDA-approved ones. See our medical review policy. Affiliate disclosure.